Abstract Details

Title Quantitative Assessment of Bradykinesia in Parkinson's Disease (PD)

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 192

Objective

Background BACKGROUND: Ordinal rating scales (e.g., UPDRS) that measure motor function in PD can be subjective and may lack sensitivity to detect subtle features. Automated quantitative assessments are of interest for both their objectivity and sensitivity.

Design/Methods DESIGN/METHODS: 40 subjects (21 patients with parkinsonism and 19 patients with other neurological disorders) were assessed with the UPDRS and MovAlyzeR, a digital writing tablet able to measure velocity and amplitude during upper extremity movements (quickly drawing lines between targets). Subjects were tested under single and dual task (saying the days of the week backwards) conditions. Group means were compared using Mann-Whitney U-tests. Relationships between UPDRS-III and quantitative motor function test scores were assessed using partial correlations.

Results RESULTS: Stroke velocity was significantly slower in parkinsonian subjects under single and dual task conditions (p=.041 for both tasks). The differences persisted for single task stroke velocity when controlling for subject age. Absolute stroke size did not vary between groups (p=.147). Total UPDRS motor scores negatively correlated with stroke velocity (single task r=-.368, p=.027; dual task r=-.495, p=.002), consistent with slowing in more advanced parkinsonism. Among UPDRS domains, the strongest correlation was with bradykinesia items (single task r=-.383, p=.021; dual task r=-.495., p=.002). Associations were also observed with rigidity and Postural Instability and Gait Disorder items. Tremor items did not correlate with stroke velocity.

Conclusions CONCLUSIONS: MovAlyzeR quantitative testing distinguished between subjects with parkinsonism and controls, and stroke velocity correlated well with UPDRS motor scores, particularly with measures of bradykinesia rather than tremor. Future studies will assess whether quantitative testing can evaluate parkinsonism and changes associated with progression or treatment more sensitively than UPDRS.

Authors/Disclosures
Alexander Pantelyat, MD, FAAN (Johns Hopkins University School of Medicine) PRESENTER	Dr. Pantelyat has received personal compensation for serving as an employee of MedRhythms, Inc.. Dr. Pantelyat has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MedRhythms, Inc.. Dr. Pantelyat has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Kelly & Ignoffo Law Group. The institution of Dr. Pantelyat has received research support from NIH/NIA.
	No disclosure on file
	No disclosure on file
Maria Pia Sormani (University of Genoa)	Maria Pia Sormani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Maria Pia Sormani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Maria Pia Sormani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Maria Pia Sormani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Maria Pia Sormani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol meyer. Maria Pia Sormani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Maria Pia Sormani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunic. Maria Pia Sormani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis, Roche. Maria Pia Sormani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Maria Pia Sormani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche.
	No disclosure on file
John E. Duda, MD (Veterans Affairs Medical Center)	Dr. Duda has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Nature Publishing Group. The institution of Dr. Duda has received research support from Department of Veterans Affairs. The institution of Dr. Duda has received research support from Michael J. Fox Foundation. The institution of Dr. Duda has received research support from Innervace, Incorporated. The institution of Dr. Duda has received research support from National Institutes of Health.
James F. Morley, MD, PhD	Dr. Morley has nothing to disclose.
Nicholas J. Maragakis, MD, FAAN (Johns Hopkins University School of Medicine)	Dr. Maragakis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UptoDate. Dr. Maragakis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apellis Pharmaceuticals. Dr. Maragakis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. An immediate family member of Dr. Maragakis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for National Basketball Association. Dr. Maragakis has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Akava. An immediate family member of Dr. Maragakis has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Johns Hopkins Howard County Medical Center. Dr. Maragakis has stock in Akava. The institution of Dr. Maragakis has received research support from NIH/NINDS. The institution of Dr. Maragakis has received research support from Department of Defense. The institution of Dr. Maragakis has received research support from Maryland Stem Cell Research Fund. Dr. Maragakis has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��